Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada's Marihuana for Medical Purposes Regulations MMPR. The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in Toronto, Canada.
Industry, Sector and Symbol
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorFinance
CIKN/A
Phone212-590-9070
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.12 million
Profitability
Miscellaneous
Employees291
Next Earnings Date8/13/2019 (Estimated)
OptionableOptionable
Cronos Group (NASDAQ:CRON) Frequently Asked Questions
What is Cronos Group's stock symbol?
Cronos Group trades on the NASDAQ under the ticker symbol "CRON."
How were Cronos Group's earnings last quarter?
Cronos Group Inc (NASDAQ:CRON) announced its quarterly earnings data on Thursday, May, 9th. The company reported $0.36 EPS for the quarter, topping the Zacks' consensus estimate of ($0.02) by $0.38. The business earned $6.47 million during the quarter, compared to the consensus estimate of $6.87 million. Cronos Group had a return on equity of 99.44% and a net margin of 2,107.83%. The firm's quarterly revenue was up 119.3% on a year-over-year basis. View Cronos Group's Earnings History.
When is Cronos Group's next earnings date?
What price target have analysts set for CRON?
9 analysts have issued 12 month target prices for Cronos Group's stock. Their predictions range from $13.00 to $30.00. On average, they anticipate Cronos Group's stock price to reach $21.0860 in the next twelve months. This suggests a possible upside of 43.0% from the stock's current price. View Analyst Price Targets for Cronos Group.
What is the consensus analysts' recommendation for Cronos Group?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last year. There are currently 4 sell ratings, 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cronos Group.
Has Cronos Group been receiving favorable news coverage?
News coverage about CRON stock has trended somewhat negative on Tuesday, InfoTrie reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cronos Group earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are some of Cronos Group's key competitors?
Some companies that are related to Cronos Group include Canopy Growth (CGC), Aurora Cannabis (ACB), Tilray (TLRY), USANA Health Sciences (USNA), CV Sciences (CVSI), Chromadex (CDXC), Canopy Rivers (RIV), Foamix Pharmaceuticals (FOMX), Mediwound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), China Jo-Jo Drugstores (CJJD), Cyanotech (CYAN), FitLife Brands (FTLF) and GLG Life Tech (GLGLF).
What other stocks do shareholders of Cronos Group own?
Who are Cronos Group's key executives?
Cronos Group's management team includes the folowing people:
- Mr. Michael Gorenstein, Chairman, Pres & CEO (Age 31)
- Mr. David Hsu, Chief Operating Officer
- Ms. Xiuming Shum, Gen. Counsel & Corp. Sec.
- Mr. Jeffrey Jacobson, Head of Sales & Bus. Devel.
- Mr. William Hilson, Chief Commercial Officer
Who are Cronos Group's major shareholders?
Cronos Group's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Morgan Stanley (0.42%), Sumitomo Mitsui Trust Holdings Inc. (0.20%), Swiss National Bank (0.17%), TD Asset Management Inc. (0.16%), Essex Investment Management Co. LLC (0.08%) and NumerixS Investment Technologies Inc (0.07%).
Which institutional investors are selling Cronos Group stock?
CRON stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Gerber Kawasaki Wealth & Investment Management, Harel Insurance Investments & Financial Services Ltd., Great West Life Assurance Co. Can, MML Investors Services LLC, TD Asset Management Inc., Ladenburg Thalmann Financial Services Inc. and Cetera Advisors LLC.
Which institutional investors are buying Cronos Group stock?
CRON stock was acquired by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Swiss National Bank, Essex Investment Management Co. LLC, NumerixS Investment Technologies Inc, AQR Capital Management LLC, State of Wisconsin Investment Board, Toronto Dominion Bank and FIL Ltd.
How do I buy shares of Cronos Group?
Shares of CRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cronos Group's stock price today?
One share of CRON stock can currently be purchased for approximately $14.75.
How big of a company is Cronos Group?
Cronos Group has a market capitalization of $4.91 billion and generates $12.12 million in revenue each year. The company earns $-14,640,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. Cronos Group employs 291 workers across the globe.
What is Cronos Group's official website?
How can I contact Cronos Group?
Cronos Group's mailing address is 720 KING STREET W SUITE 320, TORONTO A6, M5V 2T3. The company can be reached via phone at 212-590-9070.
MarketBeat Community Rating for Cronos Group (NASDAQ CRON)
MarketBeat's community ratings are surveys of what our community members think about Cronos Group and other stocks. Vote "Outperform" if you believe CRON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRON will underperform the S&P 500 over the long term. You may vote once every thirty days.
